Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Opium (Opioid) Addiction - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Opium (Opioid) Addiction - Pipeline Review, H1 2016', provides an overview of the Opium (Opioid) Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction - The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects - The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Opium (Opioid) Addiction Overview 9 Therapeutics Development 10 Pipeline Products for Opium (Opioid) Addiction - Overview 10 Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis 11 Opium (Opioid) Addiction - Therapeutics under Development by Companies 12 Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes 13 Opium (Opioid) Addiction - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Opium (Opioid) Addiction - Products under Development by Companies 17 Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes 18 Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 19 Alkermes Plc 19 Aoxing Pharmaceutical Company, Inc 20 BioDelivery Sciences International, Inc. 21 Camurus AB 22 Foresee Pharmaceuticals, LLC 23 Heron Therapeutics, Inc. 24 Indivior Plc 25 INSYS Therapeutics, Inc. 26 Omeros Corporation 27 Pfizer Inc. 28 Relmada Therapeutics, Inc. 29 Titan Pharmaceuticals, Inc. 30 Zynerba Pharmaceuticals, Inc. 31 Opium (Opioid) Addiction - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Combination Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 42 (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 (buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Buprenorphine Hemiadipate Hydrochloride - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 buprenorphine hydrochloride - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 buprenorphine hydrochloride - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 buprenorphine hydrochloride - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 buprenorphine hydrochloride depot - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 buprenorphine hydrochloride ER - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 buprenorphine hydrochloride long acting - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 buprenorphine hydrochloride SR - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 cannabidiol - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Cannabidiol - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 FP-004 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 naltrexone hydrochloride - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 naltrexone hydrochloride - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 OMS-405 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 OMS-527 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 PF-5006739 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 samidorphan l-malate - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 TA-CD - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Vaccine for Opium Addiction - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Opium (Opioid) Addiction - Recent Pipeline Updates 72 Opium (Opioid) Addiction - Dormant Projects 81 Opium (Opioid) Addiction - Discontinued Products 82 Opium (Opioid) Addiction - Product Development Milestones 83 Featured News & Press Releases 83 Mar 04, 2016: BioDelivery Sciences to provide an update on Buprenorphine Injection at the Cowen And Company 36th Annual Healthcare Conference and the 28th Annual Roth Conference 83 Feb 19, 2016: Titan Pharmaceuticals Announces Notification of FDA Action Date Extension for Probuphine 83 Feb 16, 2016: TSRI Scientists Create Vaccine Against Dangerous Designer Opioids 83 Jan 13, 2016: Segal Institute for Clinical Research Proudly Participates in Phase 3 Efficacy Trial of Long-Acting Treatment Opioid Dependence 85 Jan 12, 2016: Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction 85 Dec 30, 2015: Braeburn Pharmaceuticals and Camurus Enroll First Patient in a Phase 3 Efficacy Trial of Long-Acting Treatment for Opioid Dependence 86 Dec 15, 2015: Braeburn Pharmaceuticals and Camurus announce start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence 87 Dec 09, 2015: Braeburn Pharmaceuticals and Titan Pharmaceuticals Announce Date of FDA Advisory Committee Review of Probuphine for Opioid Addiction 87 Dec 09, 2015: Relmada Therapeutics Announces Positive Topline Results for Proof-of-Concept Study with BuTab 88 Dec 09, 2015: Relmada Therapeutics Announces Positive Topline Results for Proof-of-Concept Study with BuTab 88 Appendix 90 Methodology 90 Coverage 90 Secondary Research 90 Primary Research 90 Expert Panel Validation 90 Contact Us 90 Disclaimer 91
List of Tables
Number of Products under Development for Opium (Opioid) Addiction, H1 2016 10 Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H1 2016 19 Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company, Inc, H1 2016 20 Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International, Inc., H1 2016 21 Opium (Opioid) Addiction - Pipeline by Camurus AB, H1 2016 22 Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016 23 Opium (Opioid) Addiction - Pipeline by Heron Therapeutics, Inc., H1 2016 24 Opium (Opioid) Addiction - Pipeline by Indivior Plc, H1 2016 25 Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H1 2016 26 Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H1 2016 27 Opium (Opioid) Addiction - Pipeline by Pfizer Inc., H1 2016 28 Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H1 2016 29 Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals, Inc., H1 2016 30 Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 31 Assessment by Monotherapy Products, H1 2016 32 Assessment by Combination Products, H1 2016 33 Number of Products by Stage and Target, H1 2016 35 Number of Products by Stage and Mechanism of Action, H1 2016 37 Number of Products by Stage and Route of Administration, H1 2016 39 Number of Products by Stage and Molecule Type, H1 2016 41 Opium (Opioid) Addiction Therapeutics - Recent Pipeline Updates, H1 2016 72 Opium (Opioid) Addiction - Dormant Projects, H1 2016 81 Opium (Opioid) Addiction - Discontinued Products, H1 2016 82
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
